Retifanlimab is an investigational intravenous humanized monoclonal antibody that inhibits the activity of programmed death-1 (PD-1). By blocking PD-1, retifanlimab acts as an immune checkpoint inhibitor, freeing T cells to kill cancer cells and boosting immune system response against certain cancers. Retifanlimab is proposed as a monotherapy for locally advanced and metastatic squamous cell anal cancer (SCAC) that has progressed after platinum-based chemotherapy.

If you have a Hayes login, click here to view the full report on the Knowledge Center.